Trial Profile
A Phase II, First-in-human Dose-escalation, Double-masked, Randomized, Vehicle-controlled, Dose-response Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-102 in Subjects With Elevated Intraocular Pressure
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 May 2014
Price :
$35
*
At a glance
- Drugs AR 102 (Primary)
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Therapeutic Use
- Sponsors Aerie Pharmaceuticals
- 13 May 2014 New trial record